Nifty Pharma down 2% after U.S. announces tariff on pharma

The Indian pharmaceutical sector faced a sharp setback in stock markets after the United States announced a steep tariff on pharmaceutical imports. On September 26, the Nifty Pharma index slipped 2.14% to 21,507.20 points following U.S. President Donald Trump’s announcement of a 100% tariff on branded pharmaceutical trade.
Tariff Announcement from the U.S.
President Trump stated that the new tariff would take effect from October, doubling the cost of branded pharmaceutical imports into the American market. The move is seen as part of a broader protectionist strategy aimed at supporting domestic drug manufacturing.
Market Impact in India
The announcement immediately triggered concerns among investors, particularly because the United States remains a critical market for Indian pharmaceutical exports. Top pharma stocks came under pressure, dragging the Nifty Pharma index down by more than 2% during trading.
Why It Matters
India’s pharma industry is heavily reliant on the U.S. market, with a significant share of exports comprising branded generics and specialty drugs.
A 100% tariff would make Indian drugs less competitive in the U.S., potentially affecting sales, profit margins, and long-term growth.
The announcement also raises uncertainty about trade relations between India and the United States, adding volatility to the sector.
Looking Ahead
While the full impact will unfold in the coming weeks, analysts expect short-term turbulence for Indian pharma stocks. Companies with higher exposure to the U.S. branded drug market are likely to face the most pressure. At the same time, industry experts believe Indian policymakers may seek diplomatic channels to negotiate relief or exemptions.
For investors, the situation underscores the importance of monitoring global trade developments and their ripple effects on sectoral indices. With the tariff set to kick in from October, the Indian pharma industry braces for challenges ahead.